The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/190866

Please be advised that this information was generated on 2020-03-11 and may be subject to change.
Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer

Janine T. Hidding 1,2 • Carien H. G. Beurskens 1 • Philip J. van der Wees 2 • Wilmy C. A. M. Bos 3 • Maria W. G. Nijhuis-van der Sanden 1,2 • Hanneke W. M. van Laarhoven 3,4

Received: 8 March 2017 / Accepted: 25 September 2017 / Published online: 10 November 2017
© The Author(s) 2017. This article is an open access publication

Abstract

Purposes The purposes of this study were to investigate the incidence of lymphedema in patients with breast cancer during and after adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC), to identify predictors for development of lymphedema, and to describe consequences in daily life in relation to lymphedema.

Methods This is a prospective study with measurements before chemotherapy (T0), during chemotherapy before cycle 2 (T1), cycle 4 (T2), and 1 month after completion of treatment (T3). Volume change was monitored using tape measurements. Lymphedema was defined as ≥10% volume difference. Linear mixed-effect models were estimated to analyze differences in arm volume and consequences in daily life (total score and domain scores of the Lymph-International Classification of Functioning (ICF) questionnaire) over time and to identify treatment and patient characteristics as predictors for changes in volume.

Results Forty-eight patients completed all measurements. Volume did not change during TAC treatment. One month after treatment, volume was significantly increased compared to T0-T2, and 12 patients (25%) had developed lymphedema. Axillary lymph node dissection was associated with lymphedema (ES 2.9, 95% CI 0.02–5.7; p < 0.05). In patients with and without lymphedema, 1 month after completion (T3), the Lymph-ICF questionnaire showed significant limitations in physical function compared to T0-T2. In patients with lymphedema at T3, a significant association between volume and total score on the Lymph-ICF questionnaire on physical function and mobility activities was observed.

Conclusions One month after treatment in 12 patients (25%), volume difference increased over 10%. Axillary lymph node dissection was predictive for development of lymphedema. All patients, but more patients with lymphedema, perceived difficulties in activities in daily life after treatment.

Keywords Breast neoplasms • Lymphedema • Adjuvant chemotherapy • Activities of daily living • Quality of life

Introduction

Lymphedema is a common side effect of breast cancer treatment, usually starting within 2 years after treatment [1]. Patients with lymphedema suffer not only from swelling but also from other impairments in functions and limitations in activities in daily life, as described in the core set lymphedema based on the International Classification of Functioning (ICF) [2]. Lymphedema is defined as a volume difference between upper extremities of ≥10% [3], resulting in limitations in arm use during daily activities, emotional distress, restrictions in social activities, and limited work abilities [2, 4, 5].

The estimated incidence of lymphedema 5 years after breast cancer treatment is 16.6%, and increase in arm volume is related to axillary lymph node dissection, the number of
lymph nodes dissected, mastectomy, radiotherapy to the axilla, and a body mass index over 25 kg/m² [1, 6]. Recent studies have indicated that the use of adjuvant cytotoxic treatment may be associated with development of lymphedema after completion of treatment, especially regimens containing anthracyclines and taxanes [6–14]. Swelling may decline over time, as a result of lymphedema treatment or due to spontaneous recovery of transient swelling within 3 months [13, 14]. Adjuvant chemotherapy has been shown to improve survival in patients with early-stage breast cancer. Second and third generation schemes are more effective in survival compared to first generation schemes [15]. A frequently used third generation regimen consists of docetaxel, doxorubicin, and cyclophosphamide (TAC) [16].

Although the prevalence of lymphedema in the arm after completion of TAC has been reported [11–14], development of lymphedema during treatment with TAC and limitations in daily activities in relation to lymphedema during and after TAC are unknown. Early detection of lymphedema and consequently early intervention can lessen treatment burden and increase the cost-effectiveness of care [17]. Therefore, it is clinically relevant to obtain insight in changes in volume differences or the amount of extracellular fluid in an early stage.

The purpose of this study is to answer the following questions: (1) what is the change in arm volume during adjuvant treatment with TAC, and do patients develop lymphedema as defined by a volume difference between upper extremities of ≥ 10%, (2) which predictors for development of lymphedema can be identified, and (3) which consequences in daily life are related to the presence of lymphedema?

Methods

Study design

We conducted a prospective cohort study in which patients with unilateral breast cancer were scheduled for adjuvant cytotoxic treatment with six cycles of TAC. Patients were measured at four time points: at baseline before cycle 1 (T0), during chemotherapy before cycle 2 (T1) and cycle 4 (T2), and 1 month after the 6th cycle (T3). Three months after completion, the Lymph-ICF questionnaire was sent to the patients (T4).

Patient population

Patients, both female and male, with tumor stages I–III, scheduled for adjuvant cytotoxic treatment with TAC at the Radboud University Medical Center were invited by a specialized nurse (WB) to participate in this study. Patients were included between August 2011 and January 2015. Surgery was completed, as well as radiotherapy if indicated, before the start of TAC. Exclusion criteria were recurrence or second cancer and insufficient understanding of Dutch language for filling out the questionnaire. Formal ethical approval was waived by the Medical Ethical Committee of the Radboud University Medical Center. The study was registered under number 2011/234. All participants signed informed consent before the first measurement. We calculated the sample size based on arm volume difference as primary endpoint. A priori, a dropout of 10% was taken into account. To detect changes at a two-sided significance level of 5% and an estimated power of 80%, we planned to enroll 50 patients.

Chemotherapy

Docetaxel (75 mg/m²), doxorubicin (50 mg/m²), and cyclophosphamide (500 mg/m²) were administered intravenously on day 1 of a three-weekly cycle for a total of six courses. Dexamethasone was administered 8 mg orally twice daily for 3 days, starting the day before start of TAC during all cycles.

Measurements

Demographic and tumor characteristics, type of surgery, axillary lymph node dissection, tumor stage, nodal stage, tumor grade, adjuvant radiotherapy, radiotherapy to the axilla or supraclavicular region, weight, and height were derived from electronic health records of the included patients. Early termination of TAC or dose reduction was registered, as well as the reason for the early stop and change of cytotoxic agents. Weight was registered before the first and after the last cycle to determine body mass index (BMI) and weight changes.

Volume of both arms was measured by tape measurement [18], and impairments in functions and limitations in activities in daily life were measured by the Lymph-ICF questionnaire [19]. Measurements were performed by three physiotherapists (CB, RD, JH), experienced in measuring arm volume. Investigators were blinded for results of prior measurements. The measurement protocol was described in detail to reduce measurement error and, if possible, patients were measured by the same therapist throughout the whole study. All patients with a volume difference ≥ 10%, at any time point, were referred for treatment. Both upper limbs were measured by tape measurement with 10 cm intervals up to 40 cm, starting at the ulnar styloid process. Position of the arm during measurement was in 90° flexion of the shoulder with the elbow extended. Hands were supported on a pillow. To calculate volume, the conical formula was used [18]. Volumes between both upper extremities were converted to percentage differences (relative volume, in short mentioned as volume in this article). Tape measurement is a reliable measurement instrument, with excellent intra- and intertest-retest reliability (ICC 0.99
and 0.98, respectively) and good validity (0.80–1.00) compared to water volumetry when a standardized protocol
is used [18].

Volume differences, based on the tape measurement, were computed at all four time points. A volume difference ≥ 10% between both upper extremities was indicated as swelling or development of lymphedema [3]. To get insight in outcomes between patients without and with lymphedema 1 month after completion, and to get insight in the association between volume differences and impairments in functions and limitations in activities in daily life, the patient group was dichotomized in two categories: with lymphedema and without lymphedema 1 month after completion of TAC (T3).

The Lymph-ICF questionnaire for the upper extremity was used to get insight in impairments in functions and limitations in activities in daily life [19]. The Lymph-ICF is a quality of life questionnaire developed for patients with lymphedema, with 29 items over five domains: physical function, mental function, household activities, mobility activities, and social activities. Each item can be scored between 0 and 100 on a horizontal line of 100 mm. Domain scores and the total score can be calculated from the items, both resulting in a score between 0 and 100. A higher score means more impairment in functions or limitation in activities: scores under 25 indicate a minor problem, scores between 25 and 50 a moderate problem, and scores more than 50 a severe problem. Measurement properties of the Lymph-ICF have been studied before and showed a fair to excellent reliability for all scales (r = 0.65–0.93) compared to volume measurements [19]. Patients filled in the Lymph-ICF questionnaire at every measurement point. To get insight in recovery after TAC, 3 months after the last TAC (T4), the Lymph-ICF questionnaire was sent to the patient for a final measurement.

Statistical analysis

Descriptive analyses were used to describe patient characteristics, treatment characteristics, the number of patients with lymphedema, and the scores of the Lymph-ICF questionnaire in total and its domains.

To analyze differences in volume and consequences in daily life over time (total score and domain scores on the Lymph-ICF questionnaire) and to identify treatment and patient characteristics as predictors for changes in volume, linear mixed-effect models were used. We estimated a random intercept model with volume difference as dependent variable, and we estimated separate models with total score and domain scores of the Lymph-ICF questionnaire as dependent variables. To indicate predictors for lymphedema, univariate analysis was used to analyze the association between volume difference and type of surgery, surgery on dominant side, axillary lymph node dissection, tumor stage, nodal stage (N0 versus N1, N2, and N3), tumor grade (T1 versus T2 or 3), adjuvant radiotherapy, radiotherapy to the axilla or supraclavicular region, and change of BMI between T0 and T3. Variables with an association p < 0.20 in the univariate analysis were included into the model as independent variables.

To analyze the association between volume differences and impairments in functions and limitations in activities after completion of TAC, Pearson’s correlation coefficients between volume and the outcomes of the Lymph-ICF questionnaire (total score and domain scores) were calculated for the total population. To analyze the relation between scores of the Lymph-ICF questionnaire and lymphedema, patients were dichotomized in patients without lymphedema and patients with lymphedema at 1 month after completion of TAC (T3). In both groups, the association between the volume and the scores of the Lymph-ICF questionnaire, its five domains, and individual items of the physical function domain and mobility activities domain (T3 and T4) were analyzed, using Spearman’s correlations.

Correlations between measurement outcomes were interpreted as follows: r between 0.40 and 0.75 is fair to good; r > 0.75 is excellent [20].

For statistical analysis, SPSS version 22 was used.

Results

A total of 74 patients scheduled for adjuvant TAC were invited to participate in the study. Fifty-one patients consented to participate, one of these was male. Mean age of the included patients was 51.3 years (30–68; SD 8.5). Patient and tumor characteristics of these patients are summarized in Table 1. Two patients switched treatment to FEC (5-fluorouracil, epirubicin, and cyclophosphamide) after the third and fourth cycles. One patient was treated without docetaxel in the fourth cycle of TAC and stopped after this cycle. Finally, 48 patients completed six cycles of TAC and all follow-up measurements. Four of these 48 patients were treated with reduced dose (75%) after the third (n = 2 patients), fourth (n = 1 patient), or fifth cycle (n = 1 patient) (see Fig. 1).

Changes in arm volume and lymphedema measured by tape measurement

Mean volume did not change during treatment but increased significantly from 2.3% at T0 to 5.1% at 1 month after completion of TAC (T3) (p = 0.01) (see Table 2). In total, 15 patients showed increased volume of ≥ 10% difference in at least one measurement point. In three of the
six patients, swelling was deemed transient: volume decreased under the cutoff point of 10% volume difference within the study period, one of them without treatment. Fulfilling our definition, lymphedema was observed first in six patients during TAC treatment. These patients were referred for lymphedema treatment: two patients were indicated at baseline (T0), two before the second (T1), and two before the fourth cycle during chemotherapy (T2). One month after treatment (T3), lymphedema was observed in 12 out of 48 patients (25%).

Predictors for of lymphedema

Axillary lymph node dissection, nodal stage, axillary radiation, and difference in BMI identified between 1 month after completion of TAC (T3) and baseline (T0) were variables with a correlation \( p < 0.10 \) with volume at T3 in the univariate analysis. The linear mixed-effect model showed that axillary lymph node dissection was the only factor significantly associated with increased volume (ES 2.9%; 95% CI 0.02–5.7;
functions 1 month after treatment (see Table 4). One month after completion of TAC, in patients with lymphedema, a significant association was found between volume and the Lymph-ICF total score ($r = 0.66$), the physical function domain ($r = 0.77$), the item scores for heaviness ($r = 0.83$) and swelling ($r = 0.71$), and the mobility activities domain ($r = 0.66$), as well the items activities above the head ($r = 0.71$) and cycling ($r = 0.72$). Three months after completion of TAC, in patients with lymphedema, the significant correlation between relative volume at T3 and the total Lymph-ICF score ($r = 0.70$) and mobility activities ($r = 0.62$) remained (see Table 5).

**Discussion**

During cytotoxic treatment with TAC, we observed no significant changes in volume between upper extremities in the total study population. However, 1 month after completion of TAC, volume was increased significantly, and 25% of the patients had developed a volume difference over 10%, defined as lymphedema. Also, in this population, axillary lymph node dissection was predictive for development of lymphedema, as was reported in earlier studies as well [6, 21]. The Lymph-ICF questionnaire showed significant impairments in the physical function domain at 1 and 3 months after completion. One month after treatment, 17 patients showed at least moderate problems on the total score of the questionnaire and reported problems in physical function, household activities, mobility activities, and social activities. We observed a small decline in the number of patients with health problems between 1 and 3 months after completion of TAC.

Reported prevalence of lymphedema, measured at a comparable time point after surgery in recent studies on breast cancer, was comparable with our study at baseline [13, 14, 22, 23]. DiSipio et al. described in their systematic review a prevalence of lymphedema of 10.3% (95% CI 6.2–16.7) at the same time point as T3 in our study, after completion of cytotoxic treatment [1]. In relation to their study, the prevalence of lymphedema at the endpoint in our study is higher. This could be the effect of the adjuvant treatment with TAC as suggested in a recent study indicating docetaxel as important risk factor for onset of lymphedema, with a chance of developing lymphedema being 4.8 times higher when compared to other treatment regimens [10] and reported in earlier studies as well [7–9, 11–14]. Compared to our study, earlier studies on TAC as a risk factor for lymphedema reported a higher prevalence of lymphedema over two or more years after treatment with TAC with 33.5% [12], 42.2% [14], and 32% after treatment, declining to 23% at 6 months [13]. Although bio-impedance spectroscopy (BIS) measures extracellular fluid more adequately and good correlations between volume measurements and BIS were found in case of swelling [18, 24–26], we
decided not to add BIS in our measurement protocol to decrease patient load during the study. As results from different studies can be compared, we decided to decrease patient load during the study. The somewhat lower prevalence of lymphedema (25%) in our study may be the result of lymphedema treatment of patients with a volume difference over 10%, later onset of lymphedema, as well as recent developments in supportive care encouraging patients to stay active during treatment with at least 30 min of moderate daily physical activity [27]. Referral to physical therapy or lymphedema treatment was reported in one other study [10]. Our analysis of predictive factors for development of lymphedema early after treatment with TAC confirms the findings of Lee et al.: axillary lymph node dissection is an important risk factor for development of lymphedema [13].

Concerning the Lymph-ICF questionnaire, problems were apparent over a longer period, in patients with and without lymphedema. Looking to the results in Table 4, it can be observed that the number of patients with problems on the Lymph-ICF questionnaire differs between groups, while Tables 5 and 6 point out that volume increase is associated with more problems at the Lymph-ICF questionnaire. This

| Measurement point | Number | Mean | Standard Error | Significance | 95% confidence interval |
|-------------------|--------|------|----------------|--------------|------------------------|
| **Total score**   |        |      |                |              |                        |
| T0                | 51     | 14.63| 2.20           |              | 10.29–18.97            |
| T1                | 51     | 11.31| 2.20           | 0.29         | 6.97–15.66             |
| T2                | 49     | 12.98| 2.25           | 0.60         | 8.55–17.41             |
| T3                | 48     | 19.46| 2.27           | 0.13         | 14.98–23.93            |
| T4                | 48     | 16.52| 2.27           | 0.55         | 12.05–21.00            |
| **Physical function** | | |      |              |                        |
| T0                | 51     | 9.80 | 2.19           |              | 5.49–14.12             |
| T1                | 51     | 6.90 | 2.19           | 0.35         | 2.58–11.22             |
| T2                | 49     | 9.96 | 2.24           | 0.96         | 5.55–14.37             |
| T3                | 48     | 17.79| 2.26           | 0.01*        | 13.34–22.24            |
| T4                | 48     | 16.67| 2.26           | 0.03*        | 12.22–21.12            |
| **Mental function** | | |      |              |                        |
| T0                | 51     | 11.75| 2.23           |              | 7.36–16.13             |
| T1                | 50     | 7.74 | 2.25           | 0.21         | 3.31–12.17             |
| T2                | 49     | 8.18 | 2.27           | 0.26         | 3.71–12.66             |
| T3                | 48     | 11.90| 2.94           | 0.96         | 7.38–16.42             |
| T4                | 48     | 9.46 | 2.94           | 0.48         | 4.94–13.98             |
| **Household activities** | | |      |              |                        |
| T0                | 51     | 14.98| 2.87           |              | 9.79–20.63             |
| T1                | 51     | 13.71| 2.87           | 0.75         | 8.06–19.35             |
| T2                | 49     | 12.02| 2.93           | 0.47         | 6.26–17.78             |
| T3                | 48     | 21.38| 2.96           | 0.12         | 15.55–27.20            |
| T4                | 48     | 16.81| 2.96           | 0.66         | 10.99–22.63            |
| **Mobility activities** | | |      |              |                        |
| T0                | 51     | 18.14| 2.74           |              | 12.73–23.54            |
| T1                | 51     | 13.73| 2.74           |              | 8.32–19.13             |
| T2                | 49     | 14.00| 2.80           | 0.26         | 8.49–19.52             |
| T3                | 48     | 20.58| 2.83           | 0.29         | 15.01–26.12            |
| T4                | 48     | 19.31| 2.83           | 0.54         | 13.74–24.89            |
| **Social activities** | | |      |              |                        |
| T0                | 51     | 19.20| 3.19           |              | 12.92–25.47            |
| T1                | 51     | 16.45| 3.19           | 0.54         | 10.18–22.73            |
| T2                | 49     | 19.35| 3.25           | 0.97         | 12.94–25.75            |
| T3                | 48     | 23.79| 3.28           | 0.32         | 17.32–30.26            |
| T4                | 48     | 18.21| 3.28           | 0.83         | 11.74–25.68            |

*Significance at $p < 0.05$
Table 5  Correlations between volume measured with tape measurement and Lymph-ICF questionnaire 1 month after completion of TAC (T3) in patients without and with lymphedema

|                          | Total score | Physical function | Mental function | Household activities | Mobility activities | Social activities |
|--------------------------|-------------|-------------------|-----------------|---------------------|--------------------|------------------|
| Relative volume          | 1.000       |                   |                 |                     |                    |                  |
| Total score              |             |                   |                 |                     |                    |                  |
| Without lymphedema       |             |                   |                 |                     |                    |                  |
| Physical function        |             |                   |                 |                     |                    |                  |
| Mental function          |             |                   |                 |                     |                    |                  |
| Household activities     |             |                   |                 |                     |                    |                  |
| Mobility activities      |             |                   |                 |                     |                    |                  |
| Social activities        |             |                   |                 |                     |                    |                  |
| With lymphedema          |             |                   |                 |                     |                    |                  |

$r$ between 0.40 and 0.75 is fair to good; $r > 0.75$ is excellent
*Significance < 0.05 (two-tailed); **significance < 0.01 (two-tailed)

Table 4  Patients with moderate ($\geq 25; < 50$) and severe ($\geq 50$) problems indicated by the Lymph-ICF questionnaire after treatment with TAC

| Reported score | One month after completion (T3) | Three months after completion (T4) |
|---------------|---------------------------------|------------------------------------|
|               | $\geq 25; < 50$ | $\geq 50$ | total | $\geq 25; < 50$ | $\geq 50$ | total |
| Total score   | $\geq 25; < 50$ | 12 | 5 | 17 | $\geq 25; < 50$ | 6 | 4 | 10 |
| Without lymphedema | 9 | 3 | 12 | 4 | 3 | 7 |
| With lymphedema | 3 | 2 | 5 | 2 | 1 | 3 |
| Physical function | 10 | 4 | 14 | 6 | 4 | 10 |
| Without lymphedema | 5 | 3 | 8 | 4 | 3 | 7 |
| With lymphedema | 5 | 1 | 6 | 2 | 1 | 3 |
| Mental function | 3 | 3 | 6 | – | 4 | 4 |
| Without lymphedema | 2 | 3 | 5 | – | 3 | 3 |
| With lymphedema | 1 | – | 1 | – | 1 | 1 |
| Household activities | 11 | 6 | 17 | 6 | 5 | 11 |
| Without lymphedema | 9 | 4 | 13 | 5 | 3 | 8 |
| With lymphedema | 2 | 2 | 4 | 1 | 2 | 3 |
| Mobility activities | 9 | 7 | 16 | 11 | 6 | 17 |
| Without lymphedema | 6 | 5 | 11 | 9 | 4 | 13 |
| With lymphedema | 3 | 2 | 5 | 2 | 2 | 4 |
| Social activities | 10 | 8 | 18 | 7 | 8 | 15 |
| Without lymphedema | 7 | 5 | 12 | 7 | 5 | 12 |
| With lymphedema | 3 | 3 | 6 | – | 3 | 3 |

Patients without lymphedema $n = 36$; patients with lymphedema $n = 12$
Scores in italic: total number of patients with problems on the mentioned item
means that all patients, with or without lymphedema, experienced problems and the Lymph-ICF questionnaire revealed health problems in the whole study-population. However, lymphedema increased the scores. Compared to the literature, in a study with FEC (fluorouracil, epirubicin, and cyclophosphamide), one third of the patients still had problems as well [28] and problems related to work were reported in a recent systematic review [4]. Especially mobility activities are an indication for decreased social contacts and participation in community life and work, which are important factors for quality of life [29, 30]. Moderate- to high-intensity exercises during chemotherapy could have limited the decrease in activities during adjuvant treatment, as was reported in an earlier study in a comparable population, reporting significant positive effects of exercise on physical function, fatigue, and chemotherapy completion rates [31].

The item scores of heaviness and swelling were significantly associated with volume in patients with lymphedema. These self-reported outcomes can indicate lymphedema of the affected upper extremity [26, 32, 33], can be used as a patient’s reported outcome for lymphedema, and are supportive in the clinical decision making on volume measurement and referral for lymphedema treatment. When moderate to severe problems are reported on the Lymph-ICF questionnaire, referral to specialized health care should be considered to improve functions and activities as soon as possible [34, 35]. In agreement with a previous systematic review of the literature [6], many factors play a role in complaints of patients after medical treatment for breast cancer. For the patient as well as the healthcare provider, it is important to know the origin of the complaints. It is unclear why the item cycling within the domain mobility activities has high scores in most of the patients; probably, this can be related to reduced cardiovascular function as an adverse effect of TAC [16] and to fibroses of the breast in patients treated with lumpectomy and radiotherapy (OR 7) [36] or pain after radiotherapy of the chest wall, as was reported by Levangie et al. in 26% of the patients, leading to reduced daily activities [5]. Limitations in activities above the head can be related to declined shoulder mobility, which is often described as adverse effect of axillary node dissection and/or axillary radiotherapy, or declined muscle strength or shoulder coordination, described as adverse effects of axillary node dissection and chemotherapy [6, 37].

This is the first study describing arm volume during TAC as an objective measurement of lymphedema in combination with patient reported outcome measures on physical and mental function, household activities, mobility activities, and social activities. However, some limitations should be considered.

Preoperative measurements were not incorporated in our measurement protocol, although such measurements have been recommended in the literature [38–42]. However, the first measurement was started within 3 months postoperatively and lymphedema is rarely reported within the first

| Relative volume | Heaviness | Swelling | Strength | Tense feeling | Activities above head | Lifting heavy objects | Sleeping on affected side | Working on computer | Walking > 2 km | Cycling |
|-----------------|-----------|----------|----------|---------------|----------------------|----------------------|-------------------------|---------------------|---------------|---------|
| Heaviness       | 0.830**   |          |          |               |                      |                      |                         |                     |               |         |
| Stiffness       | 0.516     | 0.525    |          |               |                      |                      |                         |                     |               |         |
| Swelling        | 0.709**   | 0.872**  | 1.000    |               |                      |                      |                         |                     |               |         |
| Strength        | 0.550     | 0.797**  | 0.753**  | 1.000         |                      |                      |                         |                     |               |         |
| Tense feeling   | 0.421     | 0.616*   | 0.796**  | 0.753**       | 1.000                |                      |                         |                     |               |         |
| Activities above head | 0.705* | 0.774** | 0.814**  | 0.778**       | 0.618*               | 1.000                |                         |                     |               |         |
| Lifting heavy objects | 0.564 | 0.613*   | 0.434    | 0.648*        | 0.219                | 0.734**              | 1.000                   |                     |               |         |
| Sleeping on affected side | 0.348 | 0.287 | 0.113 | 0.644 | −0.157 | 0.673* | 0.850** | 1.000 |
| Working on computer | 0.500 | −1.000** | −0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 1.000 |
| Waling > 2 km | 0.295 | 0.116 | 0.095 | 0.363 | 0.329 | 0.286 | 0.277 | 0.540 | 1.000** |
| Cycling | 0.723* | 0.492 | 0.322 | 0.610 | 0.340 | 0.729* | 0.732* | 0.962** | 1.000** |

$r$ between 0.40 and 0.75 is fair to good; $r > 0.75$ is excellent

*Significance < 0.05 (two-tailed); **significance < 0.01 (two-tailed)
months post-operatively. Moreover, this time point was found as significant predictor by Sun et al. for over- and underdiagnoses [40]. Lymphedema defined as relative volume change (RVC) compared to baseline as used by Sun et al. is a different definition compared to our definition using relative volume difference (RVD) between extremities. We used RVD following the commonly used definition in the literature [1, 6]. Future studies need to point out which of the definitions is most adequate. Furthermore, patient and treatment characteristics should be analyzed in relation to volume change during a longer follow-up with more measurement occasions. A rather conservative cutoff point of 10% between both upper extremities was defined as lymphedema, based on the smallest detectable change in tape measurement (6.6%, with excellent interrater reliability (ICC inter 0.98) [18]. Probably, a cutoff point of 5% would have increased the number of patients with (subclinical) lymphedema and transient edema.

Although the sample was large enough to distinguish changes in volume difference during the study period, a larger sample size and a longer follow-up might have indicated more risk factors for development of lymphedema over time, and a higher prevalence of lymphedema, as reported in earlier studies on TAC and docetaxel [8–12, 14, 40]. As no measurements were performed between cycles 4 and 6, the exact time point of onset of lymphedema cannot be determined. A longer follow-up would have enabled the distinction between temporary swelling and persistent lymphedema. Swelling can be transient as a result of spontaneous recovery or by intervention, as reported earlier [1, 8, 10, 13, 14]. In future research and in clinical practice, volume measurements should be taken at baseline and at least in the first follow-up visit after completion of TAC. Follow-up should be extended to differentiate between temporary swelling and lymphedema, reporting lymphedema treatment as well.

Altogether, monitoring swelling seems to have added value and seems to be clinically relevant.

### Conclusion

In our population, arm volume increased significantly 1 month after treatment with TAC and in 12 out of 48 patients (25%) relative volume difference increased over 10%. Axillary lymph node dissection was predictive for development of lymphedema. After treatment with TAC, all patients, but more patients with lymphedema, perceived difficulties in activities in daily life.

### Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

### Appendix

#### Table 7 Fixed effects of the linear mixed-effect model in relation to predictive factors for increase of relative volume at T3

| Parameter                        | Estimate | Standard error | p value | 95% confidence interval |
|----------------------------------|----------|----------------|---------|-------------------------|
| Intercept                        | 1.68     | 0.63           | 0.01    | 0.44–2.93               |
| ALND                             | 2.86     | 1.17           | 0.05*   | 0.02–5.69               |
| Nodal stage                      | 1.44     | 1.09           | 0.20    | −0.72–3.60              |
| Axillary radiation               | 0.65     | 2.75           | 0.81    | −4.78–6.08              |
| BMI T3-T0                        | −0.00    | 0.00           | 0.45    | −0.01–0.00              |
| ALND * nodal stage               | −0.26    | 3.16           | 0.94    | 8.82–−8.30              |
| ALND * axillary radiation        | 297.67   | 181.87         | 0.10    | −61.30–656.64           |
| ALND * BMI T3-T0                 | 2.02     | 0.74           | 0.07    | −0.26–4.30              |
| Nodal stage * axillary radiation | −4.14    | 3.28           | 0.21    | −10.62–2.34             |
| Nodal stage * BMI T3-T0          | 0.00     | 0.48           | 1.00    | −0.95–0.96              |
| Axillary radiation * BMI T3-T0   | 0.00     | 0.00           | 0.89    | −0.01–0.01              |
| ALND * nodal stage * axillary radiation | −298.79 | 187.54  | 0.11    | −668.96–71.37           |
| ALND * nodal stage * BMI T3-T0   | −0.80    | 1.87           | 0.69    | −6.04–4.45              |
| ALND * axillary radiation * BMI T3-T0 | 310.77   | 189.37 | 0.10    | −62.99–484.54           |
| Nodal stage * axillary radiation * BMI T3-T0 | −0.00 | 0.48 | 1.00    | −0.954–0.95 |

*ALND* axillary lymph node dissection, *BMI* body mass index
References

1. DiSipio T et al (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500–515
2. Viehoff PB et al (2015) Development of consensus International Classification of Functioning, Disability and Health (ICF) core sets for lymphedema. Lymphology 48(1):38–50
3. Moffat C, Doherty D, Morgan P (2006) In: Framework TL (ed) Best practice for the management of lymphoedema. International consensus. MEP. Ltd, London
4. Zomkowski K et al (2017) Physical symptoms and working performance in female breast cancer survivors: a systematic review. Disabil Rehabil. https://doi.org/10.1080/09638288.2017.1300950
5. Levangie PK, Drouin J (2009) Magnitude of late effects of breast cancer treatments on shoulder function: a systematic review. Breast Cancer Res Treat 116(1):1–15
6. Hidding JT et al (2014) Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review. PLoS One. 9(5)
7. Hugenholz-Wamsteker W et al (2016) The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review. Eur J Cancer Care (Engl) 25(2):269–279
8. Kim M et al (2016) Identification of prognostic risk factors for transient and persistent lymphedema after multimodal treatment for breast cancer. Cancer Res Treat 48(4):1330–1337
9. Kilbreath SL et al (2016) Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast 28:29–36
10. Yang EJ et al (2016) Use of a prospective surveillance model to prevent breast cancer treatment-related lymphedema: a single-center experience. Breast Cancer Res Treat 160(2):269–276
11. Swaroop MN et al (2015) Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res Treat 151(2):393–403
12. Cariani M et al (2015) Adjuvant taxanes and the development of breast cancer-related arm lymphedema. Br J Surg 102(9):1071–1076
13. Lee MJ et al (2014) Lymphedema following taxane-based chemotherapy in women with early breast cancer. Lymphat Res Biol 12(4):282–288
14. Jung SY et al (2014) Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients. Breast Cancer Res Treat 148(1):91–98
15. http://richtlijnendatabase.nl/richtlijn/breast_cancer/breast_cancer.html. 2012, IKNL and KiMS
16. Mackey JR et al (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14(1):72–80
17. Stout NL et al (2011) Segmental limb volume change as a predictor of the onset of lymphedema in women with early breast cancer. PM R 3(12):1098–1105
18. Hidding JT et al (2016) Measurement properties of instruments for measuring of lymphedema: a systematic review. Phys Ther 96(12):1965–1981
19. Devoogdt N et al (2011) Lymphoedema Functioning, Disability and Health questionnaire (Lymph-ICF): reliability and validity. Phys Ther 91(6):944–957
20. Fleiss JL, Levin B, Paik MC (2003) Statistical methods for rates and proportions, 3rd edn. Wiley, New York
21. Bromham N et al (2017) Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev I:CD004561
22. Donker M et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310
23. Ashikaga T et al (2010) Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 102(2):111–118
24. Hayes S, Cornish B, Newman B (2005) Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up. Breast Cancer Res Treat 99(3):221–226
25. Dylke ES et al (2016) Diagnosis of upper limb lymphedema: development of an evidence-based approach. Acta Oncol 55(12):1477–1483
26. Czernieck SA et al (2010) Assessment of breast cancer-related arm lymphedema—comparison of physical measurement methods and self-report. Cancer Investig 28(1):54–62
27. Segal R et al (2017) Exercise for people with cancer: a clinical practice guideline. Curr Oncol 24(1):40–46
28. Andersen KG et al (2012) Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. Acta Oncol 51(8):1036–1044
29. Kopec JA et al (2013) Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32. J Support Oncol 11(1):22–30
30. Testa A, Iannace C, Di Libero L (2014) Strengths of early physical rehabilitation programs in surgical breast cancer patients: results of a randomized controlled study. Eur J Phys Rehabil Med 50(3):275–284
31. van Waart H et al (2015) Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial. J Clin Oncol 33(17):1918–1927
32. Norman SA et al (2009) Lymphoedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol 27(3):390–397
33. Armer JM et al (2003) Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res 52(6):370–379
34. Furmaniak Anna CA (2016) Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005001.pub3
35. Harrington S et al (2014) Patient-reported upper extremity outcome measures used in breast cancer survivors: a systematic review. Arch Phys Med Rehabil 95(1):153–162
36. Hickey BE, Francis DP, and Lehman M (2013) Sequencing of chemotherapy and radiotherapy for early breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005212.pub3
37. Goker M et al (2013) Systematic review of breast cancer related lymphedema: making a balanced decision to perform an axillary clearance. Facts Views Vis Obgyn 5(2):106–115
38. McNeely ML et al (2004) The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat 86(2):95–106
39. Springer BA et al (2010) Pre-operative assessment enables early diagnosis and recovery of shoulder function in patients with breast cancer. Breast Cancer Res Treat 120(1):135–147
40. Sun F et al (2016) The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema. Breast Cancer Res Treat 157(2):229–240
41. Ancukiewicz M et al (2011) Standardized method for quantification of developing lymphedema in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 79(5):1436–1443
42. Miller CL et al (2013) A novel, validated method to quantify breast cancer-related lymphedema (BCRL) following bilateral breast surgery. Lymphology 46(2):64–74